Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
Aurélien AmiotJérôme FilippiVered AbitbolGuillaume CadiotDavid LaharieMelanie SerreroRomain AltweggYoram BouhnikLaurent Peyrin BirouletCyrielle GillettaXavier RoblinGuillaume Pineton de ChambrunLucine VuittonAnne BourrierStephane NanceyJean-Marc GornetStephane NahonGuillaume BouguenStephanie ViennotBenjamin ParienteMathurin Fumerynull nullPublished in: Alimentary pharmacology & therapeutics (2020)
In a cohort of highly refractory patients with UC with multiple prior drug failures, ustekinumab provided steroid-free clinical remission in one-third of cases at weeks 12-16. Clinical severity and previous use of anti-TNF and vedolizumab therapies were associated with ustekinumab failure at weeks 12-16.